These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21666147)

  • 1. Response to "Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban".
    Turpie AG
    J Clin Pharmacol; 2011 Jul; 51(7):1122-3. PubMed ID: 21666147
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral anticoagulants show promise.
    Hampton T
    JAMA; 2006 Feb; 295(7):743-4. PubMed ID: 16478891
    [No Abstract]   [Full Text] [Related]  

  • 4. [Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
    Bátorová A
    Vnitr Lek; 2009 Mar; 55(3):295-301. PubMed ID: 19378862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
    Kubitza D; Haas S
    Expert Opin Investig Drugs; 2006 Aug; 15(8):843-55. PubMed ID: 16859389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ["Xa-tra-xa": opportunities and open questions about new anticoagulants].
    Beer JH
    Praxis (Bern 1994); 2011 Aug; 100(16):947. PubMed ID: 21910293
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
    MMW Fortschr Med; 2013 Sep; 155(15):56-7. PubMed ID: 24224377
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.
    Greiten LE; McKellar SH; Rysavy J; Schaff HV
    Eur J Cardiothorac Surg; 2014 May; 45(5):914-9. PubMed ID: 24306948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
    Perzborn E; Kubitza D; Misselwitz F
    Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
    Schellong S
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with rivaroxaban in mechanical valve prosthesis in an animal model.
    Aramendi JI; Mestres CA
    Eur J Cardiothorac Surg; 2014 May; 45(5):920-1. PubMed ID: 24186922
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
    Turpie AG
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1238-47. PubMed ID: 17379841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Vink R; Sohne M
    N Engl J Med; 2013 May; 368(20):1945. PubMed ID: 23675668
    [No Abstract]   [Full Text] [Related]  

  • 14. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Spyropoulos AC;
    N Engl J Med; 2013 May; 368(20):1945-6. PubMed ID: 23675665
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Alameddine R; Husari A
    N Engl J Med; 2013 May; 368(20):1944-5. PubMed ID: 23675666
    [No Abstract]   [Full Text] [Related]  

  • 16. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Derksen RJ; Mulder WM; Mulder JW
    N Engl J Med; 2013 May; 368(20):1945. PubMed ID: 23675667
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.
    Harenberg J; Marx S; Erdle S; Krämer R
    Expert Rev Hematol; 2012 Feb; 5(1):107-13. PubMed ID: 22272710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rivaroxaban for thromboprophylaxis inpatients with acute medical illness].
    Ruiz Muñoz M
    Rev Clin Esp (Barc); 2013; 213(5):257. PubMed ID: 23940851
    [No Abstract]   [Full Text] [Related]  

  • 20. A new era in secondary prevention after acute coronary syndrome.
    Roe MT; Ohman EM
    N Engl J Med; 2012 Jan; 366(1):85-7. PubMed ID: 22077849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.